Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bausch & Lomb
Pharma
Despite trial miss, Bausch + Lomb advances combo to ph. 3
Bausch + Lomb has flunked a phase 2 trial of its combination of dry-eye disease drugs Xiidra and Miebo, but will advance the combo to phase 3.
Kevin Dunleavy
Aug 25, 2026 10:46am
Verily Me, Bausch + Lomb partner up on dry eye education
Aug 6, 2026 9:35pm
Bausch + Lomb brings glaucoma into focus with awareness push
Jan 5, 2026 12:06pm
Bausch + Lomb doubles down on dry eye awareness push
Jul 1, 2025 11:16am
Bausch + Lomb re-ups 'Faces of Glaucoma' awareness campaign
Jan 7, 2025 10:25am
After M&A rumors, Bausch + Lomb confirms it's exploring a sale
Dec 12, 2024 11:26am
